Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE

4 weeks ago 16

Soumya Eswaran

Tue, February 24, 2026 astatine 6:19 AM CST 3 min read

Artisan Partners, an concern absorption company, released its fourth-quarter 2025 capitalist missive for “Artisan Mid Cap Fund”. A transcript of the missive tin beryllium downloaded here. The Fund seeks to put successful companies that person franchise characteristics, with beardown net trajectories, and are trading astatine a discount to the estimated backstage marketplace value. US equities ended a grounds twelvemonth with robust fourth-quarter gains. The Fund’s Investor Class, ARTMX, delivered -0.44%, the Advisor Class, APDMX, delivered -0.37%, and the Institutional Class, APHMX, delivered -0.35% successful the 4th fourth compared to -3.70% for the Russell Midcap® Growth Index. Continued spot successful accusation exertion (IT) and wellness attraction contributed to the show during the quarter. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Artisan Mid Cap Fund highlighted stocks similar Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is simply a biotechnology institution specializing successful processing therapies for superior and uncommon diseases. On February 23, 2026, Insmed Incorporated (NASDAQ:INSM) banal closed astatine $159.03 per share. One-month instrumentality of Insmed Incorporated (NASDAQ:INSM) was -2.22%, and its shares gained 105.20% implicit the past 52 weeks. Insmed Incorporated (NASDAQ:INSM) has a marketplace capitalization of $33.917 billion.

Artisan Mid Cap Fund stated the pursuing regarding Insmed Incorporated (NASDAQ:INSM) successful its 4th fourth 2025 capitalist letter:

"Our apical contributors successful Q4 were Argenx, Coherent and Insmed Incorporated (NASDAQ:INSM). Insmed is simply a biotechnology institution focused connected pulmonary diseases. Its pb product, ARIKAYCE®, continues to execute well, with absorption raising full-year gross guidance pursuing 22% YoY growth. The institution besides reported a beardown motorboat for Brinsupri™ (brensocatib), the archetypal approved therapy for non-cystic fibrosis bronchiectasis, generating $28 cardinal successful archetypal income with much than 2,500 patients and 1,700 prescribers. We stay encouraged by Insmed’s execution and judge Brinsupri™ is apt to thrust a important nett rhythm successful the coming quarters and years."

Insmed (INSM) Soars After Raising $650 million

Insmed Incorporated (NASDAQ:INSM) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 74 hedge money portfolios held Insmed Incorporated (NASDAQ:INSM) astatine the extremity of the 4th quarter, up from 73 successful the erstwhile quarter. While we admit the imaginable of Insmed Incorporated (NASDAQ:INSM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article